Life Science Nation Newsletter  | May 25,  2017  |  Issue 215

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (May 18  - May 24)
Opens California Subsidiary to Invest in Early Stage Medtech and Biopharma
Provides Seed Financing to Healthcare IT Startups
Invests in Preclinical & Clinical-Stage Drugs, Diagnostics and Medtech
Looks for Late Stage In-Licensing and Investment Opportunities
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

LSN is a matching platform for early stage drugs, devices, diagnostics and healthcare IT and those partners who seek to invest in them. LSN has taken 5 years and 25 staff to develop an integrated partnering and funding platform that fulfils a significant unmet need that players in the life science ecosystem have faced - how to find relevant matches and start a dialogue that uncovers a mutual fit that leads to a successful investment transaction. Many of LSN's global strategic partners have been aided--either directly or indirectly-in enhancing their pipelines and product offerings with this platform. In these cases, LSN acts as key information source, a feeder of technology assets, or as a catalyst for creating and executing opportunities for new revenue channels.

LSN created a fully integrated platform of interrelated products and services that enable buyers (pharma, medical device, equity investors), and sellers (early stage life science companies) to connect based on mutual fit. Using this suite of products and services, LSN can source, vet, rank, package and introduce companies to potential partners with an unrivaled reach in the early stage life science arena. Buyers can find technology assets and sellers can find compelling partners that are a fit for their stage of development and products...

By Natasha Eldridge, RESI Conference Manager, LSN

RESI Partnering launched on Monday, and the activity level is already incredible. LSN has been collecting and analyzing RESI Partnering data ever since RESI 1 in September 2013. Within our first day post launch, we saw a 30% increase in the number of meeting requests compared to our data from last year. This activity in the system has resulted in the number of confirmed meetings nearly doubling daily since Monday, a testament to the efficiency of the RESI Partnering's matching capability.

It is exciting to see this kind of growth, especially since this will be the first time RESI will be in San Diego, but this acceleration in meeting requests and confirmations demonstrates the importance of getting on board as soon as possible; as we noted last week, The Early Entrepreneur Gets the Meetings.

Register today because the sooner you are in the RESI Partnering Platform, the greater your chances are to get the best meetings with investors, companies, and strategic partners.

By Lucy Parkinson, Director of Research, LSN

The medical device industry is consolidating rapidly, and many entrepreneurs find the medtech fundraising landscape challenging to navigate. However, there are a great diversity of early stage device investors out there looking for deals. This RESI panel brings together device investors from US and international VCs, a major device firm, and a private investment group to discuss how they assess medical device opportunities, and how an entrepreneur can build a productive dialogue with their firm.

Moderated by David Cassak (CEO, Innovation In Medtech), the panelists are:
  • Lu Zhang (Managing Partner, NewGen Capital)
  • JJ Desai (Chief Operating Officer, JLABS & CDI @ TMC)
  • Anuja Royan (Managing Director, Mithril Capital Management)
  • Omid Arkhavan (Investment Principal, MVM Life Science Partners)